Pathophysiology and diagnosis of cancer drug induced cardiomyopathy

Cardiovascular Toxicology

Volumn 7, Issue 2, 2007, Pages 61-66

  Zuppinger, Christian ^a   Timolati, Francesco ^a   Suter, Thomas M ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Anthracycline; Cancer; Cardiomyocytes; Cardiotoxicity; Diagnosis; Trastuzumab

Indexed keywords

ALDOSTERONE ANTAGONIST; ALKYLATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IMATINIB; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB; VINCA ALKALOID;

ANGINA PECTORIS; BRADYCARDIA; BREAST CANCER; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG MECHANISM; ECG ABNORMALITY; HEART ARRHYTHMIA; HEART CONTRACTION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LEUKEMIA; LUNG CARCINOMA; LYMPHOMA; MYOCARDITIS; OVARY CANCER; PATHOPHYSIOLOGY; PERICARDITIS; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; SARCOMA; SIDE EFFECT;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARDIOMYOPATHIES; HUMANS;

EID: 34548319126     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12012-007-0016-2     Document Type: Conference Paper

References (42)

1. Ewer, M. S., & Lippman, S. M. (2005). Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. Journal of Clinical Oncology, 23, 2900-2902.
2. Felker, G. M., Thompson, R. E., Hare, J. M., Hruban, R. H., Clemetson, D. E., Howard, D. L., Baughman, K. L., & Kasper, E. K. (2000). Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. The New England Journal of Medicine, 342, 1077-1084.
3. Mann, D. L. (1999). Mechanisms and models in heart failure: A combinatorial approach. Circulation, 100, 999-1008.
4. Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003). Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer, 97, 2869-2879.
5. Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995). Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. The New England Journal of Medicine, 332, 1738-1743.
6. Singal, P. K., & Iliskovic, N. (1998). Doxorubicin-induced cardiomyopathy. The New England Journal of Medicine, 339, 900-905.
7. Bristow, M. R., Mason, J. W., & Daniels, J. R. (1978). Monitoring of anthracycline cardiotoxicity. Cancer Treatment Reports, 62, 1607-1608.
8. Mackay, B., Ewer, M. S., Carrasco, C. H., & Benjamin, R. S. (1994). Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastructural Pathology, 18, 203-211.
9. Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., & Schlattner, U. (2006). New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. Journal of Molecular and Cellular Cardiology, 41, 389-405.
10. Hasinoff, B. B. (1998). Chemistry of dexrazoxane and analogues. Seminars in Oncology, 25, 3-9.
11. Gille, L., & Nohl, H. (1997). Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radical Biology & Medicine, 23, 775-782.
12. Doroshow, J. H. (1983). Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Research, 43, 460-472.
13. Maeda, A., Honda, M., Kuramochi, T., & Takabatake, T. (1998). Doxorubicin cardiotoxicity: diastolic cardiac myocyte dysfunction as a result of impaired calcium handling in isolated cardiac myocytes. Japanese Circulation Journal, 62, 505-511.
14. Kang, Y. J., Chen, Y., & Epstein, P. N. (1996). Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. The Journal of Biological Chemistry, 271, 12610-12616.
15. Campbell, D. L., Stamler, J. S., & Strauss, H. C. (1996). Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. The Journal of General Physiology, 108, 277-293.
16. Arai, M., Tomaru, K., Takizawa, T., Sekiguchi, K., Yokoyama, T., Suzuki, T., & Nagai, R. (1998). Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. Journal of Molecular and Cellular Cardiology, 30, 243-254.
17. Dodd, D. A., Atkinson, J. B., Olson, R. D., Buck, S., Cusack, B. J., Fleischer, S., & Boucek, R. J. Jr. (1993). Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. Journal of Clinical Investigation, 91, 1697-1705.
18. Goldhaber, J. I. (1996). Free radicals enhance Na+/Ca2+ exchange in ventricular myocytes. The American Journal of Physiology, 271, H823-833.
19. Lim, C. C., Zuppinger, C., Guo, X., Kuster, G. M., Helmes, M., Eppenberger, H. M., Suter, T. M., Liao, R., & Sawyer, D. B. (2004). Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. Journal of Biological Chemistry, 279, 8290-8299.
20. Aries, A., Paradis, P., Lefebvre, C., Schwartz, R. J., & Nemer, M. (2004). Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 101, 6975-6980.
21. Xiong, Y., Liu, X., Lee, C. P., Chua, B. H., & Ho, Y. S. (2006). Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase. Free Radical Biology & Medicine, 41, 46-55.
22. Adderley, S. R., & Fitzgerald, D. J. (1999). Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. Journal of Biological Chemistry, 274, 5038-5046.
23. Maejima, Y., Adachi, S., Morikawa, K., Ito, H., & Isobe, M. (2005). Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation. Journal of Molecular and Cellular Cardiology, 38, 163-174.
24. Sawyer, D. B., Zuppinger, C., Miller, T. A., Eppenberger, H. M., & Suter, T. M. (2002). Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation, 105, 1551-1554.
25. Timolati, F., Ott, D., Pentassuglia, L., Giraud, M. N., Perriard, J. C., Suter, T. M., & Zuppinger, C. (2006). Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. Journal of Molecular and Cellular Cardiology, 41, 845-854.
26. Cote, G. M., Miller, T. A., Lebrasseur, N. K., Kuramochi, Y., & Sawyer, D. B. (2005). Neuregulin-1alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Experimaental Cell Research, 311, 135-146.
27. Kang, Y. J., Chen, Y., Yu, A., Voss-McCowan, M., & Epstein, P. N. (1997). Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. Journal of Clinical Investigation, 100, 1501-1506.
28. Slamon, D., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J. M., Pegram, M., Baselga, J., & Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine, 344, 783-792.
29. Drimal, J., Zurova-Nedelcevova, J., Knezl, V., Sotnikova, R., & Navarova, J. (2006). Cardiovascular toxicity of the first line cancer chemotherapeutic agents: doxorubicin, cyclophosphamide, streptozotocin and bevacizumab. Neuro Endocrinology Letters, 27(Suppl 2), 176-179.
30. Kerkela, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., Rosenzweig, A., Salomon, R. N., Van Etten, R. A., Alroy, J., Durand, J. B., & Force, T. (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine, 12, 908-916.
31. Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., & Slamon, D. (1999). Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene, 18, 2241-2251.
32. Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., Cameron, D., Dowsett, M., Barrios, C. H., Steger, G., Huang, C. S., Andersson, M., Inbar, M., Lichinitser, M., Lang, I., Nitz, U., Iwata, H., Thomssen, C., Lohrisch, C., Suter, T. M., Ruschoff, J., Suto, T., Greatorex, V., Ward, C., Straehle, C., McFadden, E., Dolci, M. S., & Gelber, R. D. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England Journal of Medicine, 353, 1659-1672.
33. Strasser, F., Betticher, D. C., & Suter, T. M. (2001). Trastuzumab and breast cancer. The New England Journal of Medicine, 345, 996.
34. Sawyer, D. B., Zuppinger, C., Miller, T. A., Eppenberger, H. M., & Suter, T. M. (2002). Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1 beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation, 105, 1551-1554.
35. Pentassuglia, L., Timolati, F., Seifriz, F., Abudukadier, K., Suter, T. M. & Zuppinger, C. (2007). Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Experimental Cell Research in press.
36. Ewer, M. S., Vooletich, M. T., Durand, J. B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005). Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. Journal of Clinical Oncology, 23, 7820-7826.
37. Tan-Chiu, E., Yothers, G., Romond, E., Geyer, C. E. Jr., Ewer, M., Keefe, D., Shannon, R. P., Swain, S. M., Brown, A., Fehrenbacher, L., Vogel, V. G., Seay, T. E., Rastogi, P., Mamounas, E. P., Wolmark, N., & Bryant, J. (2005). Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. Journal of Clinical Oncology, 23, 7811-7819.
38. Dindogru, A., Barcos, M., Henderson, E. S., & Wallace, H. J. Jr. (1978). Electrocardiographic changes following adriamycin treatment. Medical and Pediatric Oncology, 5, 65-71.
39. Lipshultz, S. E., Rifai, N., Sallan, S. E., Lipsitz, S. R., Dalton, V., Sacks, D. B., & Ottlinger, M. E. (1997). Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation, 96, 2641-2648.
40. Nousiainen, T., Jantunen, E., Vanninen, E., Remes, J., Vuolteenaho, O., & Hartikainen, J. (1999). Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. European Journal of Haematology, 62, 135-141.
41. Kouloubinis, A., Kaklamanis, L., Ziras, N., Sofroniadou, S., Makaritsis, K., Adamopoulos, S., Revela, I., Athanasiou, A., Mavroudis, D., & Georgoulias, V. (2007). ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. International Journal of Cardiology.
42. Shureiqi, I., Cantor, S. B., Lippman, S. M., Brenner, D. E., Chernew, M. E., & Fendrick, A. M. (2002). Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy. British Journal of Cancer, 86, 226-232.